PTN Stock Overview
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Palatin Technologies, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.69 |
52 Week High | US$5.05 |
52 Week Low | US$1.35 |
Beta | 0.89 |
1 Month Change | 14.46% |
3 Month Change | -50.47% |
1 Year Change | -30.00% |
3 Year Change | -86.89% |
5 Year Change | -93.61% |
Change since IPO | -99.62% |
Recent News & Updates
Recent updates
Shareholder Returns
PTN | DE Biotechs | DE Market | |
---|---|---|---|
7D | -4.2% | -5.1% | -2.0% |
1Y | -30.0% | -21.1% | -0.3% |
Return vs Industry: PTN underperformed the German Biotechs industry which returned -21.1% over the past year.
Return vs Market: PTN underperformed the German Market which returned -0.3% over the past year.
Price Volatility
PTN volatility | |
---|---|
PTN Average Weekly Movement | 23.5% |
Biotechs Industry Average Movement | 5.0% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.0% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: PTN's share price has been volatile over the past 3 months.
Volatility Over Time: PTN's weekly volatility has increased from 18% to 23% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1986 | 34 | Carl Spana | palatin.com |
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company’s lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases.
Palatin Technologies, Inc. Fundamentals Summary
PTN fundamental statistics | |
---|---|
Market cap | €27.87m |
Earnings (TTM) | -€32.90m |
Revenue (TTM) | €6.66m |
3.9x
P/S Ratio-0.8x
P/E RatioIs PTN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PTN income statement (TTM) | |
---|---|
Revenue | US$7.10m |
Cost of Revenue | US$23.14m |
Gross Profit | -US$16.04m |
Other Expenses | US$19.01m |
Earnings | -US$35.04m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -2.17 |
Gross Margin | -225.96% |
Net Profit Margin | -493.74% |
Debt/Equity Ratio | 0% |
How did PTN perform over the long term?
See historical performance and comparison